vs

Side-by-side financial comparison of EAGLE FINANCIAL SERVICES INC (EFSI) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

STANDARD BIOTOOLS INC. is the larger business by last-quarter revenue ($19.6M vs $16.4M, roughly 1.2× EAGLE FINANCIAL SERVICES INC). On growth, EAGLE FINANCIAL SERVICES INC posted the faster year-over-year revenue change (21.3% vs -11.5%). EAGLE FINANCIAL SERVICES INC produced more free cash flow last quarter ($24.3M vs $-23.1M). Over the past eight quarters, EAGLE FINANCIAL SERVICES INC's revenue compounded faster (1.5% CAGR vs -12.2%).

Ally Financial Inc. is an American bank holding company incorporated in Delaware and headquartered at Ally Detroit Center in Detroit, Michigan. The company provides financial services including car finance, online banking via a direct bank, corporate lending, vehicle insurance, mortgage loans, and other related financing services such as installment sale and lease agreements.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

EFSI vs LAB — Head-to-Head

Bigger by revenue
LAB
LAB
1.2× larger
LAB
$19.6M
$16.4M
EFSI
Growing faster (revenue YoY)
EFSI
EFSI
+32.8% gap
EFSI
21.3%
-11.5%
LAB
More free cash flow
EFSI
EFSI
$47.4M more FCF
EFSI
$24.3M
$-23.1M
LAB
Faster 2-yr revenue CAGR
EFSI
EFSI
Annualised
EFSI
1.5%
-12.2%
LAB

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
EFSI
EFSI
LAB
LAB
Revenue
$16.4M
$19.6M
Net Profit
$-34.7M
Gross Margin
48.5%
Operating Margin
33.6%
-168.5%
Net Margin
-177.4%
Revenue YoY
21.3%
-11.5%
Net Profit YoY
-28.8%
EPS (diluted)
$1.10
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EFSI
EFSI
LAB
LAB
Q4 25
$16.4M
Q3 25
$22.4M
$19.6M
Q2 25
$20.6M
$21.8M
Q1 25
$4.8M
$40.8M
Q4 24
$22.0M
Q3 24
$18.4M
$22.1M
Q2 24
$16.5M
$22.5M
Q1 24
$15.9M
$45.5M
Net Profit
EFSI
EFSI
LAB
LAB
Q4 25
Q3 25
$5.6M
$-34.7M
Q2 25
$5.3M
$-33.5M
Q1 25
$-7.0M
$-26.0M
Q4 24
Q3 24
$3.4M
$-26.9M
Q2 24
$3.2M
$-45.7M
Q1 24
$2.5M
$-32.2M
Gross Margin
EFSI
EFSI
LAB
LAB
Q4 25
Q3 25
48.5%
Q2 25
48.8%
Q1 25
48.4%
Q4 24
Q3 24
54.9%
Q2 24
46.1%
Q1 24
53.1%
Operating Margin
EFSI
EFSI
LAB
LAB
Q4 25
33.6%
Q3 25
30.9%
-168.5%
Q2 25
31.8%
-118.1%
Q1 25
-189.0%
-80.8%
Q4 24
36.8%
Q3 24
21.6%
-120.9%
Q2 24
22.9%
-134.5%
Q1 24
19.1%
-132.2%
Net Margin
EFSI
EFSI
LAB
LAB
Q4 25
Q3 25
25.0%
-177.4%
Q2 25
25.6%
-153.7%
Q1 25
-145.8%
-63.8%
Q4 24
Q3 24
18.6%
-122.0%
Q2 24
19.3%
-203.3%
Q1 24
16.0%
-70.6%
EPS (diluted)
EFSI
EFSI
LAB
LAB
Q4 25
$1.10
Q3 25
$1.04
$-0.09
Q2 25
$0.98
$-0.09
Q1 25
$-1.53
$-0.07
Q4 24
$1.74
Q3 24
$0.97
$-0.07
Q2 24
$0.89
$-0.12
Q1 24
$0.72
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EFSI
EFSI
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$129.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$188.8M
$399.7M
Total Assets
$1.9B
$539.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EFSI
EFSI
LAB
LAB
Q4 25
Q3 25
$129.4M
Q2 25
$158.6M
Q1 25
$150.9M
Q4 24
Q3 24
$210.6M
Q2 24
$269.8M
Q1 24
$287.1M
Total Debt
EFSI
EFSI
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Stockholders' Equity
EFSI
EFSI
LAB
LAB
Q4 25
$188.8M
Q3 25
$185.6M
$399.7M
Q2 25
$179.6M
$424.5M
Q1 25
$176.5M
$454.6M
Q4 24
$119.0M
Q3 24
$117.8M
$489.3M
Q2 24
$111.1M
$510.3M
Q1 24
$107.7M
$577.3M
Total Assets
EFSI
EFSI
LAB
LAB
Q4 25
$1.9B
Q3 25
$1.9B
$539.6M
Q2 25
$2.0B
$557.0M
Q1 25
$1.9B
$579.6M
Q4 24
$1.9B
Q3 24
$1.9B
$681.5M
Q2 24
$1.8B
$708.7M
Q1 24
$1.8B
$777.7M
Debt / Equity
EFSI
EFSI
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EFSI
EFSI
LAB
LAB
Operating Cash FlowLast quarter
$25.8M
$-22.2M
Free Cash FlowOCF − Capex
$24.3M
$-23.1M
FCF MarginFCF / Revenue
148.6%
-118.1%
Capex IntensityCapex / Revenue
8.6%
4.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$39.7M
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EFSI
EFSI
LAB
LAB
Q4 25
$25.8M
Q3 25
$8.2M
$-22.2M
Q2 25
$2.6M
$-20.7M
Q1 25
$5.8M
$-30.3M
Q4 24
$18.8M
Q3 24
$7.5M
$-27.9M
Q2 24
$-1.8M
$-39.0M
Q1 24
$6.8M
$-62.5M
Free Cash Flow
EFSI
EFSI
LAB
LAB
Q4 25
$24.3M
Q3 25
$7.8M
$-23.1M
Q2 25
$2.3M
$-22.6M
Q1 25
$5.3M
$-35.3M
Q4 24
$17.7M
Q3 24
$7.3M
$-30.1M
Q2 24
$-2.2M
$-41.0M
Q1 24
$6.7M
$-63.3M
FCF Margin
EFSI
EFSI
LAB
LAB
Q4 25
148.6%
Q3 25
35.0%
-118.1%
Q2 25
11.2%
-103.6%
Q1 25
110.1%
-86.6%
Q4 24
80.6%
Q3 24
39.6%
-136.4%
Q2 24
-13.6%
-182.2%
Q1 24
41.9%
-138.9%
Capex Intensity
EFSI
EFSI
LAB
LAB
Q4 25
8.6%
Q3 25
1.7%
4.5%
Q2 25
1.3%
8.7%
Q1 25
11.2%
12.4%
Q4 24
4.6%
Q3 24
1.3%
10.2%
Q2 24
2.6%
8.6%
Q1 24
0.6%
1.7%
Cash Conversion
EFSI
EFSI
LAB
LAB
Q4 25
Q3 25
1.47×
Q2 25
0.49×
Q1 25
Q4 24
Q3 24
2.19×
Q2 24
-0.57×
Q1 24
2.65×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EFSI
EFSI

Asset Management$6.0M37%
Other$3.8M23%
Interchange Fees$3.5M22%
Overdrawn Account Fees$1.6M10%
Brokerage Commissions$1.4M9%

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons